Providing safe, efficacious, and affordable therapies to patients with severe localized chronic diseases.
How we do it
Unlocking the full potential of non-replicative Herpes Simplex Virus 1 (nrHSV-1) vectors as a powerful gene therapy platform. This allows for the expression of large genes under the control of sophisticated regulatory elements, in a safe and redosable manner.
We are passionate about making a difference for patients with chronic diseases. We are developing a powerful gene therapy platform, and the critical manufacturing infrastructure, to do this.
We are exploiting the natural properties of the Herpes Simplex Virus 1 (HSV-1) to establish lifelong latency in peripheral neurons in harmony with its human host. This should ensure safe, highly specific, and durable expression of the disease modifying transgene to treat the local roots of severe, chronic diseases. We are designing vectors that we can easily engineer from a smart backbone and efficiently manufacture using our specific cell line in a GMP compliant process.
Our initial focus is peripheral nervous system disorders. We are experts in engineering vectors with specific promoters to achieve relevant targeted effects in a specific neuronal subset of sensory or autonomic nervous system.
We are developing a rich pipeline of vectors targeting different indications. Our most advanced project targets Type C neurons for the treatment of neurogenic bladder disorders, starting with the one affecting patients with spinal cord injuries.
Funding and Support
BPI France, France’s Ministry of Research, and the Ile-de-France region have funded the company with multiple non-dilutive loans and grants as part of their work to deliver the French government’s policy of support for French start-ups by fuelling their R&D to accelerate innovation through grants and loans.